Genetic Profiling in Atopic Dermatitis: Skin Barrier and Th2 Variants Linked to Dupilumab Respon

10 Apr 20265 min read0 viewsJournal Feed

GIST

BackgroundAtopic dermatitis (AD) is a clinically heterogeneous immune-mediated skin disorder. The lack of reliable clinical stratification tools and predictive biomarkers for therapeutic response remains a critical unmet need to optimize treatment and advance precision dermatology.ObjectiveTo investigate the association between genetic variants and AD phenotypes and response to Dupilumab as a potential approach to individualize therapy in moderate-to-severe AD.Methods120 patients with moderate-to-severe AD treated with Dupilumab were enrolled at two Italian centers.

Clinical data, including phenotypes, severity, and comorbidities, were collected at baseline and after 48 weeks treatment with Dupilumab. Its efficacy was assessed as EASI75 and EASI90 achievements at week 48.

Genotyping of 521 SNPs was performed using next-generation sequencing (NGS). Cluster analysis and univariate logistic regression explored associations between genetic profiles and clinical variables.ResultsNGS-based genotyping enabled the stratification of patients into four distinct genetic clusters, each characterized by unique combinations of polymorphisms in skin barrier–related genes, namely FLG and KIF3A.

Specific SNPs in additional barrier-related genes (RPTN rs3001978, TH2LCRR rs2158177 and rs3091307) and Th2 pathway genes (IL4R rs1805016, STAT6 rs324011) were differentially distributed across the clusters.

Clinical Editorial

Study scope and design

Investigated associations between genetic variants and clinical phenotypes of atopic dermatitis (AD) and response to Dupilumab in moderate-to-severe disease.
Prospective cohort of 120 AD patients treated with Dupilumab at two Italian centers.
Baseline and 48-week follow-up data collected, including phenotype, severity, and comorbidities; efficacy assessed by achieving EASI75 and EASI90 at week 48.
Genotyping performed for 521 single-nucleotide polymorphisms (SNPs) using next-generation sequencing.
Analytical approach included cluster analysis to define genetic subgroups and univariate logistic regression to relate genotypes to clinical variables.

Genetic architecture and phenotypic clustering

NGS-based profiling segregated patients into four distinct genetic clusters.
Each cluster was defined by unique combinations of skin barrier gene polymorphisms, notably in FLG and KIF3A.
Additional barrier-related variants (RPTN rs3001978, TH2LCRR rs2158177 and rs3091307) and Th2 pathway gene variants (IL4R rs1805016, STAT6 rs324011) showed differential distribution across clusters.
A combined pattern involving KIF3A and FLG variants was strongly linked to a generalized eczema phenotype.

Clinical correlations and comorbidity signals

Some allele variants correlated with specific comorbid profiles: conjunctivitis (FLG), rhinitis (KIF3A), bronchial asthma (IL5RA), and elevated IgE levels (ADAM33).
The data suggest certain genetic signatures may align with broader atopic manifestations and IgE-driven phenotypes.

Predictors of Dupilumab response

FLG rs749682384 and IL6R rs2228145 variants emerged as indicators of favorable response to Dupilumab.
Conversely, RPTN rs3001978 and TSLP rs2289276 variants associated with inadequate or failed therapeutic response.

Interpretation and practical relevance

The study identifies genetic signatures in skin barrier and Th2 signaling pathways that correspond to clinical phenotypes and different Dupilumab outcomes.
Findings propose a potential role for genotypic profiling to inform personalized therapy choices in moderate-to-severe AD.

Limitations and reporting gaps

The provided content does not specify effect sizes, statistical significance values, confidence intervals, or validation in independent cohorts.
No details on potential confounders or harmonization across centers beyond baseline and 48-week data collection.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

Front ImmunolRelated by Conditionasthma

Association of early-life human rhinovirus and respiratory syncytial virus infections with childhood asthma: a cohort study in Suzhou, China

Research Highlights • 20 May 2026

Feed Metadata

Source

Frontiers in Immunology